drugset / Trial / NCT03931057

The Use of ADV6209 for Premedication in Pediatric Anesthesia

NCT03931057 ↗

Phase 4 Completed 80 enrolled Medical University of Vienna
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the effect of ADV6209, a new oral Midazolam formulation, on preoperative anxiety and sedation levels in paediatric anaesthesia Primary Objective: Sedation score (mYPAS) 30 min after administration of the premedication drug Secondary Objective: Acceptance of anaesthesia mask induction Acceptance of oral administration of the premedication drug

Timeline

Start
2020-11-16
Primary completion
2021-09-17
Completion
2021-09-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ADV6209 Unknown 0.25 mg/kg Oral
Comparator Midazolam Small molecule 0.25 mg/kg Oral

Indications

No indication recorded.